Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Review Article

Peri-procedural Anticoagulation in Catheter Ablation for Atrial Fibrillation: A Review

Author(s): Dimitrios A. Vrachatis*, Georgios Giannopoulos, Charalambos Kossyvakis, Vasiliki Panagopoulou, Manolis Vavuranakis, Theodore G. Papaioannou, ">Stamatina Pagoni, ">Vlasios N. Pyrgakis, Michael W. Cleman and Spyridon G. Deftereos

Volume 23, Issue 9, 2017

Page: [1334 - 1345] Pages: 12

DOI: 10.2174/1381612822666161205115101

Price: $65

Abstract

Catheter ablation for rhythm control in atrial fibrillation has been recognized as an established treatment. Patients with atrial fibrillation suffer from an increased risk of thromboembolic events. Long-term stroke risk and mortality have been shown to be reduced after catheter ablation, still the procedure per se is associated with an additive peri-procedural thromboembolic risk. Maintenance of the thrombotic - bleeding equilibrium in such patients during interventional procedures is compelling. Lack of data from randomized studies along with the recent introduction of novel oral anticoagulants in clinical practice has resulted in a wide variance of antithrombotic treatment approaches. Procedural interruption of anticoagulants, switching of anticoagulation scheme (i.e. from novel oral anticoagulants to vitamin K antagonists), bridging with heparin, timing of re-initiation of therapy and/or utilization of novel oral anticoagulants have all been points of dispute. In the present review we present the available data regarding optimal peri-procedural anticoagulation strategies in patients undergoing catheter ablation for atrial fibrillation.

Keywords: Radiofrequency, cryoablation, VKA, NOAC, warfarin, dabigatran, rivaroxaban, apixaban.


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy